Purchase this article with an account.
R. G. Ellis-Behnke, Y. Liang, S. W. H. Cheung, K.-F. So, D. K. C. Tay; Using a Self-Assembling Nanopeptide to Achieve Ocular Hemostasis Without Causing Clotting or Secondary Inflammation. Invest. Ophthalmol. Vis. Sci. 2010;51(13):427.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Hemostasis is a major problem in ocular surgical procedures. There are few effective methods to stop bleeding without causing secondary damage.
We made a laceration to the the sclera, cornea, or limbal vein in hamsters and rats and then applied a self-assembling nanopeptide (SAP) to the wound. For intraocular procedures we were able to directly inject the material at the site of injury.
Complete hemostasis was achieved in less than 15 seconds when applied intraocularly, or directly to the surface of the sclera. The SAP stopped bleeding in less than 15 seconds and stabilized the local environment, without causing blockage of the vascular flow or an immune response. The novel therapy stops bleeding without the use of pressure, cauterization, vasoconstriction, coagulation, or cross-linked adhesives. The self-assembling solution is nontoxic and nonimmunogenic, and the breakdown products are amino acids, which are tissue building blocks that can be used to repair the site of injury.
This is the first use of nanotechnology to achieve ocular hemostasis in less than 15 seconds, both internally and externally, without causing secondary inflammation.
This PDF is available to Subscribers Only